Transactions in Connection with Share Buy-back Program
08 Aprile 2024 - 11:44AM
Transactions in Connection with Share Buy-back Program
Company Announcement
COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq:
GMAB). On March 15, 2024, Genmab announced the initiation
of a share buy-back program to repurchase up to DKK 3.5 billion
worth of shares.
The share buy-back program is expected to be completed no later
than December 16, 2024.
The following transactions were executed under the program from
April 1, 2024 to April 5, 2024:
|
|
Trading Platform |
No. of shares |
Average price (DKK) |
Total value (DKK) |
|
Accumulated through last
announcement |
|
121,123 |
|
249,025,183.97 |
|
April 1, 2024 |
XCSE |
0 |
|
|
|
|
CEUX |
0 |
|
|
|
|
AQEU |
0 |
|
|
|
|
TQEX |
0 |
|
|
|
|
Total |
0 |
|
|
|
April 2, 2024 |
XCSE |
9,860 |
2,094.64 |
|
|
|
CEUX |
6,971 |
2,095.99 |
|
|
|
AQEU |
882 |
2,101.72 |
|
|
|
TQEX |
1,140 |
2,096.48 |
|
|
|
Total |
18,853 |
2,095.58 |
39,507,990.48 |
|
April 3, 2024 |
XCSE |
10,101 |
2,053.50 |
|
|
|
CEUX |
6,502 |
2,049.85 |
|
|
|
AQEU |
1,069 |
2,049.49 |
|
|
|
TQEX |
1,352 |
2,045.15 |
|
|
|
Total |
19,024 |
2,051.43 |
39,026,451.88 |
|
April 4, 2024 |
XCSE |
11,421 |
2,072.95 |
|
|
|
CEUX |
6,961 |
2,072.52 |
|
|
|
AQEU |
1,586 |
2,076.27 |
|
|
|
TQEX |
1,425 |
2,079.81 |
|
|
|
Total |
21,393 |
2,073.51 |
44,358,702.12 |
|
April 5, 2024 |
XCSE |
7,553 |
2,061.18 |
|
|
|
CEUX |
5,082 |
2,061.15 |
|
|
|
AQEU |
515 |
2,061.91 |
|
|
|
TQEX |
860 |
2,061.11 |
|
|
|
Total |
14,010 |
2,061.19 |
28,877,270.50 |
|
Total |
|
73,280 |
|
151,770,414.98 |
|
Accumulated under the program |
|
194,403 |
|
400,795,598.95 |
Details of each transaction are included as an appendix to this
announcement.
Following these transactions, Genmab holds 1,054,745 shares as
treasury shares, corresponding to 1.60% of the total share capital
and voting rights.
The share buy-back program is undertaken in accordance with
Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated
Regulation (EU) 2016/1052, also referred to as the “Safe Harbour
Regulation.” Further details on the terms of the share buy-back
program can be found in our company announcement no. 22 dated March
15, 2024.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For 25 years,
its passionate, innovative and collaborative team has invented
next-generation antibody technology platforms and leveraged
translational, quantitative, and data sciences, resulting in a
proprietary pipeline including bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies, and antibody-drug conjugates. To help develop
and deliver novel antibody therapies to patients, Genmab has formed
20+ strategic partnerships with biotechnology and pharmaceutical
companies. By 2030, Genmab’s vision is to transform the lives of
people with cancer and other serious diseases with
knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S., and Tokyo, Japan. For more information, please
visit Genmab.com and follow us on LinkedIn and
X.Contact: Marisol
Peron, Senior Vice President, Global Communications & Corporate
AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com This Company Announcement contains
forward looking statements. The words “believe,” “expect,”
“anticipate,” “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports,
which are available on www.genmab.com and the risk factors included
in Genmab’s most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Company Announcement nor to confirm such statements to reflect
subsequent events or circumstances after the date made or in
relation to actual results, unless required by law. Genmab A/S
and/or its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped
Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®
and KYSO®.
Company Announcement no. 27 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 240408_CA27_Transactions in connection with SBBP
- 240408_Appendix_SBBP Transactions April 1-5
Grafico Azioni Genmab AS (TG:GE9)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Genmab AS (TG:GE9)
Storico
Da Nov 2023 a Nov 2024
